BACKGROUND Statins are first-line therapy for cardiovascular disease prevention, but their systemic effects across
) (5, 6, 17, 22, 30, 31) . The NMR metabolomics platform has been extensively used in epidemiological and genetic studies (5, 17, 22, 30, 31) , and the experimentation has been described elsewhere (17, 29) . NMR spectral data from 3 molecular windows with anno- Table 2 ). (12, 37) . These results are consistent with omega-3 fatty acids being primarily bound to the phospholipids, which only account for some 30% of the lipids in LDL particles (36) . Monounsaturated and saturated fatty acids were decreased to a broadly similar extent as total triglycerides and phospholipids, respectively, which is coherent with the main fatty acid compositions for these lipid classes (36) . The changes in the relative fatty acid balance due to statin therapy were modest. Although lower levels of the ratio of omega-6 fatty acids to total fatty acids have been associated with higher cardiovascular risk (5, 38) , evidence for a causal relation is lacking.
The overall consistency between the genetic and longitudinal association patterns indicate that the various fatty acid modulations are on-target effects of HMGCR inhibition rather than due to cholesterolindependent properties of statins (37) .
We also assessed whether statin therapy would be associated with biomarkers in various nonlipid pathways. GlycA, a measure of systemic inflammation and a biomarker for CVD and all-cause mortality (5, 6, 32, 33, 39) , was modestly lowered, in accordance with the proposed anti-inflammatory properties of statins (7, 8 lower circulating LDL-C levels (13, 19) , Although Mendelian randomization of drug targets has been used previously (19, 20, 34) 
